Metrics as of 10/16/2026, 08:36 AM (Berlin time), refresh in progress.
Surrozen Stock
Surrozen, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Craig C. Parker
- Employees
- 44
- Market cap
- $187 M
- IPO
- 11/01/2021
Surrozen, Inc., a biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. Its lead product candidates are antibody-based therapeutics that target various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea,…
Surrozen stock: price history
1D
+5.6%
1W
-10.4%
1M
+41.1%
6M
-17.3%
YTD
+10.9%
1Y
+82.3%
2Y
+134.3%
5Y
-73.6%
10Y
–
Next earnings date
Next earnings date
06/11/2026 (in 20 days)
Volatility around earnings
~35% stronger price swings than usual
Ask the agents about Surrozen
Analyst assessment of Surrozen
PRICE TARGET LOW
US$54.00
CONSENSUS
US$54.00
MEDIAN
US$54.00
PRICE TARGET HIGH
US$54.00
0
STRONG BUY
4
BUY
0
HOLD
2
SELL
0
STRONG SELL
6
TOTAL · Buy
As of: 25/09/2026
Surrozen stock metrics
P/E
-0.61
P/B
-1.34
EV/EBITDA
-0.28
RETURN ON EQUITY
-22.9%
NET MARGIN
1,003.5%
DEBT/EQUITY
-0.03
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
43.8%
FLOAT SHARES
3,273,629
AVG. DAILY VOLUME (30D)
862,777
Insider transactions (SEC)
TCG Crossover GP II, LLC
TCG Crossover GP II, LLC
Parker Craig C
Williams Charles O
Li Yang
Institutional holders
Dividends & Stock splits
Comparable stocks
Frequently asked questions about Surrozen stock
What does Surrozen do?
Surrozen, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Craig C. Parker, the company employs around 44 people.
The IPO was on 11/01/2021; the stock trades on NASDAQ under the ticker SRZN.
What do analysts say about Surrozen stock?
6 analysts rate the stock, the consensus is Buy (as of 25/09/2026).
The average price target is US$54.00, ranging from US$54.00 to US$54.00, with a median of US$54.00.
This is an external assessment, not a statement by Market Jury.
When does Surrozen report next?
The next earnings date is 06/11/2026.
Around past earnings, price swings were roughly 35% stronger than usual.
Does Surrozen pay a dividend?
No, Surrozen currently does not pay a dividend.
Which stocks are comparable to Surrozen?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Surrozen stock analyzed?
Clicking "Analyze stock" lets five strategies assess Surrozen against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.